| Grant number: | 12/50359-2 |
| Support Opportunities: | Research Grants - Research Partnership for Technological Innovation - PITE |
| Start date: | September 01, 2013 |
| End date: | December 31, 2015 |
| Field of knowledge: | Health Sciences - Pharmacy - Medicines Analysis and Control |
| Agreement: | GlaxoSmithKline |
| Principal Investigator: | Jean Leandro dos Santos |
| Grantee: | Jean Leandro dos Santos |
| Principal researcher abroad: | Jean Leandro dos Santos |
| Institution abroad: | GlaxoSmithKline , England |
| Host Institution: | Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil |
| City of the host institution: | Araraquara |
| Company: | Glaxosmithkline Brasil Ltda |
| Company city: | Rio de Janeiro |
Abstract
Sickle Cell Disease (SCD) is characterized by a punctual mutation (GTG to GAG) at the sixth codon of the β-globin gene what leads to the substitution of glutamic acid to valine residue in the gene for β-globin chain. Nowadays, hydroxyurea (HU) is the only drug approved to treat the disease. However, the drug has several adverse effects such as mielosuppression and genotoxicity in long term therapy. AH these factors together justify the discovery of new drugs to treat SCD symptoms. Resveratrol, a stilbenoid, is a phytoaiexin produced naturally by several plants and it is present in large quantity in red wine. It has been reported that this compound demonstrated potent antioxidant, antiinflamatory and analgesic effect useful to treat SCD symptoms. In addition, some studies have shown that resveratrol is able to induce gamma-globin gene expression. Nitric oxide has an important role in SCD. The beneficial effects of NO include: vasodilation, inhibition of platelet aggregation and induction of gamma globin gene expression. We have previously reported that nitric oxide donor compounds are also able to induce gamma-globin gene expression and fetal hemoglobin. In a continuing effort to develop new candidate drugs to treat hemoglobinophaties symptoms (such as SCD) with improved pharmacodynamic profile, we propose here the design, synthesis, and pharmacological evaluation of new resveratrol derivatives (compounds 1-12), obtained by molecular hybridization of the prototypes resveratrol (1) and NO donors subunits represented by furoxan and organic nitrate esters. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
PROCESSO DE OBTENÇÃO DE COMPOSTOS DERIVADOS ESTILBÊNICOS, COMPOSTOS DERIVADOS ESTILBÊNICOS E SEUS USOS BR 10 2016 017243 8 - Universidade Estadual de Campinas Unicamp ; Universidade Estadual Paulista Júlio de Mesquita Filho (Unesp) . Jean Leandro Dos Santos; Aylime Castanho Bolognesi Merchior Jesuíno; Priscila Longhin Bosquesi De Oliveira; Aline Renata Pavan; Carolina Lanaro; Chung Man Chin; Fernando Ferreira Costa - January 2016, 01